Sign Up Today and Learn More About Moderna Therapeutics Stock
Invest in or calculate the value of your shares in Moderna Therapeutics or other pre-IPO companies through EquityZen's platform.
Moderna Therapeutics Stock
Moderna Therapeutics specializes in drug discovery and drug development based on messenger RNA.
About Moderna Therapeutics Stock
Founded
2010
Headquarters
Cambridge, MA, US
Total Funding
1.8B
Industries
Software, Artificial Intelligence, Data and Analytics
Moderna Therapeutics develops messenger RNA therapeutics. Itprovides in vivo drug modality that produces human proteins or antibodies inside patient cells. Moderna Therapeutics also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. It focuses on disease areas, such as inherited genetic disorders, hemophilic and blood factors, and oncology.
Moderna Therapeutics Press Mentions
Stay in the know about the latest news on Moderna Therapeutics
Human Testing Begins Earlier Than Expected For U.S. Coronavirus Vaccine
Wall Streets Journal • Mar 16, 2020
Recruitment Begins for First Test of Experimental Coronavirus Vaccine
Wall Streets Journal • Mar 04, 2020
Moderna opens manufacturing site in Massachussets to advance its mRNA pipeline
In-PharmaTechnologist.com • Jul 23, 2018
Moderna's $110M Norwood site built with expansion hopes
Boston Business Journal • Jul 17, 2018
Moderna Opens New Manufacturing Site in Norwood, MA
Business Wire (press release) • Jul 17, 2018
Investors in Moderna Therapeutics
Discover investors in Moderna Therapeutics stock and explore their portfolio companies
Moderna Therapeutics Management
Leadership team at Moderna Therapeutics
Chief Executive Officer
Stéphane Bancel
President
Stephen Hoge
Join now and verify your accreditation status to gain access to:
- Moderna Therapeutics current valuation
- Moderna Therapeutics stock price
- Available deals in Moderna Therapeutics and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Moderna Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Moderna Therapeutics through EquityZen funds. These investments are made available by existing Moderna Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Moderna Therapeutics stock?
Shareholders can sell their Moderna Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
